How is Japanese Encephalitis Virus Vaccine (Intramuscular Route) dosed?
The Japanese encephalitis virus vaccine (Ixiaro) is given intramuscularly, typically into the muscle of the upper arm or thigh. It is administered in two doses, with the second dose given 28 days after the first dose. It is crucial to receive both doses at least 7 days before traveling out of the country. If you miss the second dose, consult your doctor for an additional appointment as soon as possible.
What is the dosage form of Japanese Encephalitis Virus Vaccine (Intramuscular Route)?
The dosage form of this vaccine is a suspension.
How is Japanese Encephalitis Virus Vaccine (Intramuscular Route) administered?
This vaccine is administered as a shot into the muscle of your upper arm or thigh. It is given in 2 doses, with the second dose scheduled 28 days after the first dose. It is important to receive both doses at least 7 days before traveling out of the country. If you miss the second shot, you should contact your doctor to reschedule as soon as possible.
What are common precautions when taking Japanese Encephalitis Virus Vaccine (Intramuscular Route)?
Common precautions when taking this vaccine include:
- Allergies: Inform your healthcare professional if you have had any unusual or allergic reactions to this vaccine or other medications. Mention any other types of allergies, such as to foods, dyes, preservatives, or animals.
- Bleeding disorders: Use with caution if you have a bleeding disorder, as the vaccine may increase the risk of bleeding or bruising.
- Immune deficiency or immune system problems: The vaccine may not work properly or cause side effects to worsen in individuals with immune system issues.
- Pregnancy and breastfeeding: Information regarding the vaccine's use during pregnancy and breastfeeding is limited. Consult your doctor before receiving the vaccine if you are pregnant, planning to become pregnant, or breastfeeding.
- Childhood: Appropriate studies have not been performed on the relationship of age to the effects of the vaccine in children younger than 2 months of age. Safety and efficacy have not been established.
- Geriatric: The vaccine has not demonstrated geriatric-specific problems that would limit its usefulness in elderly individuals.
It is essential to follow your healthcare professional's instructions for the proper use of this vaccine. Always discuss the potential risks and benefits of the vaccine with your healthcare provider before receiving it.